Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy - The New England Journal of Medicine - 2018
Brief Summary:
In patients with cardiac amyloidosis, the protein stabilizer tafamidis results in a 13.4% absolute reduction in overall mortality and a 22% absolute reduction in yearly cardiovascular hospitalization at 30 months compared to placebo. Tafamidis use was also associated with improvements in heart-failure related quality of life and functional status.Reference: http://www.ncbi.nlm.nih.gov/pubmed/30145929
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you